Novo stock split conditional on U.S. approval for Tresiba
COPENHAGEN Jan 31 (Reuters) - Danish group Novo Nordisk said an approval of insulin Tresiba in the Unites States was a condition for a decision to split the company's share.
"It is one condition that must be met. Whether there are multiple conditions, we keep to ourselves," chairman Stone Scheiby told Reuters on Thursday.
On Thursday, Novo nudged up its sales and profit forecasts for this year after strong sales of modern insulins and diabetes drug Victoza helped deliver a 16 percent rise in fourth-quarter revenue. (Reporting by Mette Fraende; Editing by Dan Lalor)
- Air strike kills 15 civilians in Yemen by mistake: officials
- North Korea executes leader's powerful uncle in rare public purge |
- Student opens fire at Colorado high school, wounds two classmates
- Man arrested for suspected suicide plot to blow up Kansas airport |
- Hawaii official who released Obama birth certificate dies in plane crash